A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)

Trial Profile

A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Intepirdine (Primary)
  • Indications Lewy body disease
  • Focus Registrational; Therapeutic Use
  • Acronyms HEADWAY-DLB
  • Sponsors Axovant Sciences
  • Most Recent Events

    • 02 Nov 2017 According to an Axovant Sciences media release, the company is re-evaluating endpoints of this trial and plans a discussion with the U.S. FDA to determine registration pathway. Top-line data are expected to be reported in January 2018.
    • 27 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
    • 27 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top